---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Mechanism of action"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Mechanism of action. Topics: Complete estrogen receptor antagonist and selective estrogen receptor degrader, Blockade of AF1 and AF2 compared with selective estrogen receptor modulators, Rationale for blocking both activation functions, Absence of agonist activity, and 11 further topics. 15 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/mechanism-of-action"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Mechanism of action

<a id="heading-2.1.2.6.1"></a>

## 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

### Complete estrogen receptor antagonist and selective estrogen receptor degrader

> “Palazestrant (OP-1250) is a novel oral, complete estrogen receptor antagonist (CERAN) and selective ER degrader (SERD) that acts by blocking both transcriptional activation function domains, AF1 and AF2, required for the estradiol-generated transcriptional activity of ER”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.1-2"></a>

### Blockade of AF1 and AF2 compared with selective estrogen receptor modulators

> “Selective estrogen receptor modulators (SERMs) block only the AF2 domain, leaving the AF1 domain active and capable of gene transcription. Palazestrant is a complete ER antagonist (CERAN) and selective ER degrader (SERD) that acts by blocking both AF1 and AF2 domains to completely block ER-driven transcriptional activity.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.1-3"></a>

### Rationale for blocking both activation functions

> “Transcription via AF1 in the N terminus is hormone-independent and can be promoted by a range of growth factors. For complete inhibition of ER-driven transcription, both AF1 and AF2 must be blocked.”

Source: [Ng et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12163657/)

<a id="topic-2.1.2.6.1-4"></a>

### Absence of agonist activity

> “OP-1250, like fulvestrant, has no agonist activity on the ER and completely blocks estrogen-induced transcriptional activity.”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="topic-2.1.2.6.1-5"></a>

### Inhibition of AF1-dependent activity in uterine cells

> “Elacestrant demonstrated partial agonist activity, with maximum response of 24%; imlunestrant, fulvestrant, and OP-1250 did not induce measurable AP activity.”
> “imlunestrant, fulvestrant, and OP-1250 completely inhibited activity with IC50 values of 32, 9.4, and 6.4 nmol/L, respectively”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="topic-2.1.2.6.1-6"></a>

### Estrogen receptor degradation in breast cancer cells

> “OP-1250 degrades ERα with comparable potency to fulvestrant (DC50 0.52 nmol/L and 0.56 nmol/L, respectively; Emax 62% and 69%, respectively)”
> “OP-1250 treatment reduced ERα protein levels by 63% relative to vehicle in MCF7 and 72% in CAMA-1 cells”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="topic-2.1.2.6.1-7"></a>

### Proteasome-dependent degradation

> “In MCF7 cells, degradation of ERα by OP-1250 was observed as early as 2 hours after treatment, levels reduced in a time-dependent manner, and degradation was blocked by treatment with the proteasome inhibitor MG-132”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="topic-2.1.2.6.1-8"></a>

### Antagonism of residual receptor after degradation

> “Palazestrant promotes ER degradation at levels similar to that of fulvestrant and greater than that of elacestrant”
> “However, the presence of residual ER protein has been detected in vitro with these treatments”
> “Therefore, palazestrant demonstrates robust CERAN activity that completely blocks ER-induced transcription, ensuring full inhibition of any residually available ER remaining from its SERD activity.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-2.1.2.6.1-9"></a>

### Receptor selectivity

> “OP-1250 demonstrated no agonist-like cross-reactivity on glucocorticoid, progesterone, or androgen receptors. Inhibition of agonist-induced androgen receptor transcriptional activity was detected only at >1 μmol/L OP-1250”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="topic-2.1.2.6.1-10"></a>

### Ligand-binding domain conformation

> “Structural biology studies confirmed the binding of 21 in ERα and the resulting movement of H12, consistent with an antagonist receptor conformation.”

Source: [Ng et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12163657/)

<a id="topic-2.1.2.6.1-11"></a>

### Activity against ESR1 Y537S and D538G mutant receptors

> “In AP assays conducted with mutant Ishikawa cells, OP-1250 displayed favorable potency against both mutants, comparable to that of fulvestrant”
> “In both AP and proliferation assays, CERANs showed reduced potency in the mutant cell lines relative to wild-type.”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="topic-2.1.2.6.1-12"></a>

### Antiproliferative potency in estrogen-stimulated cells

> “OP-1250 demonstrated a promising efficacy profile, with IC50 values of 1.4–1.6 nmol/L and favorable Emax values.”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="topic-2.1.2.6.1-13"></a>

### Corepressor NCoR1 recruitment

> “Palazestrant and fulvestrant, complete ER antagonists, induced a strong increase in luminescence, indicating potent recruitment of NCoR1 to ERα (Figure 3B).”
> “Palazestrant induces strong NCoR1–ERα recruitment at low concentrations (~1 nM).”
> “4OH-tamoxifen, lasofoxifene and vepdegestrant do not reach a maximum effect (Emax ) of 100% indicating incomplete recruitment.”

Source: [Barratt et al. (2026)](https://olema.com/wp-content/uploads/2026/04/Olema_AACR_2026_Poster-2950_Final-Digital-Poster.pdf)

<a id="topic-2.1.2.6.1-14"></a>

### Company summary of the NCoR1 findings

> “In a split-luciferase assay, palazestrant was shown to fully recruit the corepressor, NCoR1, enabling complete estrogen receptor (ER) antagonism.”

Source: [Olema Oncology AACR 2026 preclinical data announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-preclinical-data-palazestrant-and-op)

<a id="topic-2.1.2.6.1-15"></a>

### Earlier hypothesis for AF1 inhibition

> “While the mechanism of AF1 inhibition by CERANs such as OP-1250 has not been determined, we hypothesize that this may occur through recruitment of ER corepressor proteins such as NCoR, as suggested previously”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
